Interleukin, OralDNA take tooth loss risk test to US
This article was originally published in Clinica
Interleukin Genetics is set to make its PST genetic test for risk of periodontal disease available in the US through diagnostic firm OralDNA Labs. The two companies have entered a non-exclusive marketing, sales and distribution agreement for the test that will see OralDNA pay Interleukin (Waltham, Massachusetts) a set fee for each individual test that is sold. OralDNA will be responsible for the marketing costs of the test, which is aimed at the $70-96bn US dental market. According to Brentwood, Tennessee-based OralDNA, the addition of the PST test to its portfolio will complement its existing products, including the MyPerioPath test for pathogenic bacteria in the gums, and benefit the US dental community. Specific financial details of the deal were not disclosed.